HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines

AIDS Reviews

Volumn 11, Issue 1, 2009, Pages 39-51

  de Mendoza, Carmen ^a,b   Anta, Lourdes ^a   García, Federico ^a   Pérez Elías, Jesús ^a   Gutiérrez, Félix ^a   Libre, Josep M ^a   Menéndez Ariías, Luis ^a   Dalmau, David ^a   Soriano, Vincent ^a  

^a Platform for Drug Resistance of the Spanish AIDS Research Network   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Drug resistance; HIV 1; Resistance guidelines; Resistance interpretation

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LEUCINE; LOPINAVIR; LYSINE; MARAVIROC; METHIONINE; PHENYLALANINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THREONINE; TIPRANAVIR; TYROSINE; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE; CHEMOKINE RECEPTOR CCR5;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; DRUG ACTIVITY; GENE DELETION; GENE INSERTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SPAIN; VIRUS CELL INTERACTION; VIRUS RESISTANCE; ALGORITHM; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MOLECULAR GENETICS; MUTATION; VIROLOGY;

ALGORITHMS; AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INTEGRASE INHIBITORS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEASE INHIBITORS; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN;

EID: 65549114234     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Clavel F, Hance A. HIV drug resistance. N Engl J Med. 2004;350: 1023-35.
2. Anderson J, Jiang H, Ding X, et al. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses. 2008;24:685-94.
3. Vray M, Maynard J, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1 infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS088). Antivir Ther. 2003;8:427-34.
4. von Hentig N, Babacan E, Staszewski S, et al. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. Antivir Ther. 2007;12:1237-46.
5. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice:The HAVANA trial. AIDS. 2002;16:209-18.
6. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1: December 2008. Top HIV Med. 2008;16:138-45.
7. Beerenwinkel N, Schmidt B, Walter H, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predict phenotype from genotype. Proc Natl Acad Sci USA. 2002;99:8271-6.
8. Wang K, Samudrala R, Mittler J. Antivirogram or Phenosense: a comparison of their reproducibility and analysis of their correlation. Antivir Ther. 2004;9:703-12.
9. Sevin A, de Gruttola V, Nijhuis M, et al. Methods for investigation of the relationship between drug-susceptibility phenotype and HIV type 1 genotype with applications to AIDS clinical trials group 333. J Infect Dis. 2000;182:59-67.
10. Wang D, Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis. 2003;188:653-60.
11. Shafer R, Schapiro J. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008;10:67-84.
12. Rhee S, Taylor J, Wadhera G, et al. Genotypic predictors of HIV type 1 drug resistance. Proc Natl Acad Sci USA. 2006;103:17355-60.
13. Beerenwinkel N, Daumer M, Oette M, et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 2003;31:3850-5.
14. De Luca A, Cingolani A, di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic HIV-1 drug resistance. J Infect Dis. 2003;187:1934-43.
15. Vercauteren J, Vandamme A. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res. 2006;71:335-42.
16. De Luca A, Cozzi-Lepri A, Perno C, et al. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virologic outcomes of the initial HAART by distinct systems. Antivir Ther. 2004;9:743-52.
17. Nogales C, Serrano C, Bernal S, et al. Study of resistance using the TRUGENE HIV-1 genotyping system and analysis of agreement between rule-based algorithms and virtual phenotyping. Enferm Infecc Microbiol Clin. 2005;23:149-55.
18. Eshleman S, Crutcher G, Petrauskene O, et al. Sensitivity and specificity of the ViroSeq HIV-1 genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol. 2005;43:813-7.
19. De Mendoza C, Rodriguez C, Colomina J, et al. Resistance to nonnucleoside reverse transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis. 2005;41:1350-4.
20. Martínez-Picado J, Gutierrez C, de Mendoza C, et al. Surveillance of drug resistance and HIV subtypes in newly diagnosed patients in Spain during year 2004. Antivir Ther. 2005;10:S131.
21. De Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses. 2007;23:879-85.
22. Dalmau D, Klimkait T, Telenti A. Resistance to new anti-HIV agents: problems in the pathway of drug registration. Antivir Ther. 2005;10: 867-72.
23. Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analog mutation profiles: factors associated with acquiring specific profiles and their impact on the virologic response to therapy. Antivir Ther. 2005;10: 791-802.
24. Winters M, Shafer R, Jellinger R, et al. HIV type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother. 1997;41:757-62.
25. Miller M. K65R, TAMs and tenofovir. AIDS Rev. 2004;6:22-33.
26. Barrios A, de Mendoza C, Martin-Carbonero L, et al. Role of baseline HIV genotype as a predictor of viral response to tenofovir in heavily pretreated patients. J Clin Microbiol. 2003;41:4421-3.
27. Vallejo A, Olivera M, Rubio A, et al. Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen. Antiviral Res. 2004;61:129-32.
28. Svarovskaia E, Margot N, Bae A, et al. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr. 2007;46:174-80.
29. De Mendoza C, Soriano V, Briones C, et al. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J Acquir Immune Defic Syndr. 2000;23:279-81.
30. Whitcomb J, Parkin N, Chappey C, Hellmann N, Petropoulos C. Broad nucleoside reverse transcriptase inhibitor cross-resistance in HIV type 1 clinical isolates. J Infect Dis. 2003;188:992-1000.
31. Shafer R, Rhee S, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21: 215-23.
32. Garcia-Lerma J, Nidtha S, Blumoff K, et al. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naïve persons. Proc Natl Acad Sci USA. 2001;98:13485-7.
33. Ingrand D, Weber J, Boucher C, et al. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS related complex patients: sustained reductions on viral markers. AIDS. 1995;9:1323-9.
34. Miller V, Sturmer M, Staszewski S, et al. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS. 1998;12:705-12.
35. Marcelin A, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother. 2005;49;1739-44.
36. Blanco J, Biglia A, de Lazzari E, et al. Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations. AIDS. 2006;20:1891-2.
37. Svedhem V, Bergroth T, Lidman K, Sönnerborg A. Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure. HIV Med. 2007;8:504-10.
38. Llibre J, Bonjoch A, Iribarren J, et al. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1 infected patients with multidrug-resistant virus: a multicentre pilot study. HIV Med. 2008;62:909-13.
39. McColl D, Chappey C, Parkin N, Miller M. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther. 2008; 13:189-97.
40. Cases-González C, Franco S, Martínez M, Menéndez-Arias L. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. J Mol Biol. 2007;365:298-309.
41. Villena C, Prado J, Puertas M, et al. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical HIV type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J Virol. 2007;81:4713-21.
42. Miller M, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189:837-46.
43. Gallego O, de Mendoza C, Labarga P, et al. Long-term outcome of HIV-infected patients with multinucleoside resistant genotypes. HIV Clin Trials. 2003;4:372-81.
44. Zhang Z, Hamatake R, Hong Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother. 2004;15:121-34.
45. Briones C, Soriano V, Dona C, et al. Can early failure with nevirapine be rescued with efavirenz? J Acquir Immune Defic Syndr. 2000;24:76-8.
46. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002;18:835-8.
47. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75:4999-5008.
48. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-5.
49. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773-82.
50. Madruga J, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment experienced HIV-1 infected patients in DUET-1: week results from a randomised, double-blind, placebo controlled trial. 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
51. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC-125 (etravirine) in treatment experienced HIV-1 infected patients in DUET-2: 24 week results from a randomised, double-blind, placebo controlled trial. Lancet. 2007;370:39-48.
52. Nadler J, Berger D, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24 weeks analysis. AIDS. 2007;21:F1-10.
53. Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther. 2007;12(Suppl):34.
54. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine: multivariate analyses on the pooled Duet-1 and Duet-2 clinical trial data. Antivir Ther. 2008;13:A26.
55. Poveda E, Garrido C, de Mendoza C, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;60:1409-10.
56. Poveda E, de Mendoza C, Pattery T, et al. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS. 2008;22:2395-8.
57. De Mendoza C, Valer L, Ribera E, et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials. 2006;7:163-71.
58. Marcelin A, Flandre P, de Mendoza C, et al. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Antivir Ther. 2007;12:247-52.
59. Marcelin A, Chazallon C, Gérard L, et al. External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients. J Acquir Immune Defic Syndr. 2006;42:127-8.
60. Vora S, Marcelin A, Günthard H, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS. 2006;20:35-40. 61. Dronda F, Antela A, Pérez-Elias M, et al. Rescue therapy with oncedaily atazanavir based regimens for antiretroviral-experienced HIV-infected patients. J Acquir Immune Defic Syndr. 2006;42:258-9.
61. King M, Rode R, Cohen-Codar I, et al. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2007;51:3067-74.
62. Maillard A, Chapplain J, Tribut O, et al. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavirritonavir treatment response in HIV type 1 protease inhibitor-experienced patients. J Clin Virol. 2007;38:131-8.
63. Marcelin A, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in HIV type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47:594-600.
64. Masquelier B, Assoumou K, Descamps D, et al. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J Antimicrob Chemother. 2008;61:1362-8.
65. De Mendoza C, Valer L, Bacheler L, et al. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS. 2006;20:1071-4.
66. Colonno R, Rose R, McLaren C, et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004; 189:1802-10.
67. Delaugerre C, Mathez D, Peytavin G, et al. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS. 2007;21:1210-3.
68. Martinez-Picado J, Wrin T, Frost S, et al. Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with HIV type 1. J Virol. 2005;79:5907-13.
69. Sista P, Wasikowski B, Lecocq P, et al. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts. J Clin Virol. 2008;42:405-8.
70. Baxter J, Schapiro J, Boucher C, et al. Genotypic changes in HIV protease associated with reduced susceptibility and virological response to the protease inhibitor tipranavir. J Virol. 2006;80:10794-801.
71. Scherer J, Boucher C, Baxter J, et al. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted mutation score. 6th European drug resistance workshop. March, 2008. Budapest [abstract 94].
72. Scherer J, Schapiro J, Maggiolo F, et al. Improved tipranavir weighted score predicts virologic response in diverse treatment-experienced patient populations. 7th European HIV Drug Resistance Workshop. Stockholm, Sweden. March 2009 (in press)
73. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel HIV type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-21.
74. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379-88.
75. De Meyer S, Dierynck I, Lathouwers E, et al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment experience patients on power 1, 2, 3 and DUET-1 and 2. Antivir Ther. 2008;13:A33.
76. Pellegrin I, Wittkop L, Joubert L, et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther. 2008;13:271-9.
77. Martinez-Picado J, Savara A, Sutton L, D'Aquila R. Replicative fitness of protease inhibitor-resistant mutants of HIV-1. J Virol. 1999; 73:3744-52.
78. Velazquez-Campoy A, Muzammil S, Ohtaka H, et al. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr Drug Targets Infect Disord. 2003;3: 311-28.
79. Blanco J, Biglia M, Arnedo M, et al. Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. AIDS. 2005;19:829-31.
80. Kantor R, Katzenstein D. Polymorphisms in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003;5:25-35.
81. Kantor R, Katzenstein D, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112.
82. Snoeck J, Kantor R, Shafer R, et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of HIV are subtypes dependent. Antimicrob Agents Chemother. 2006;50:694-701.
83. Poveda E, de Mendoza C, Parkin N, et al. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS. 2008;22:611-6.
84. Vergne L, Stuyver L, Van Houtte M, et al. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol. 2006;36:43-9.
85. Cabrera C, Marfil S, García E, et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS. 2006; 20:2075-80.
86. Poveda E, Rodés B, Labernardière J, et al. Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol. 2004; 74:21-8.
87. Poveda E, Rodés B, Lebel-Binay S, et al. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol. 2005;34:295-301.
88. Holguin A, Rodriguez de Arellano E, Soriano V. Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. AIDS Res Hum Retroviruses. 2007;23:1067-74.
89. Loutfy M, Raboud J, Montaner J, et al. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. Antiviral Res. 2007;75:58-63.
90. Poveda E, Briz V, Paraskevis D, et al. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses. 2007;23:1078-82.
91. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother. 2005;49:1113-9.
92. Soriano V, Geretti A, Perno C, et al. Optimal use of maraviroc in clinical practice. AIDS. 2008;22:2231-40.
93. Gulick R, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-41.
94. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008; 359:1442-55.
95. Wilkin T, Su Z, Kuritzkes D, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007; 44:591-5.
96. Brumme Z, Goodrich J, Mayer H, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466-74.
97. De Mendoza C, Rodriguez C, Garcia F, et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother. 2007; 59:698-704.
98. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359-71.
99. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using HIV-1 variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909-20.
100. Moncunill G, Armand-Ugón M, Pauls E, Clotet B, Esté J. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS. 2008;22:23-31.
101. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359: 339-54.
102. Cooper D, Steigbigel R, Gatell J, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359: 355-65.
103. Grinsztejn B, Nguyen B, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-9.
104. Pommier Y, Johnson A, Marchand C. Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov. 2005;4:236-48.
105. Hazuda D, Miller M, Nguyen B, for the P005 Study Team. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antivir Ther. 2007;12(Suppl):10.
106. Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in HIV type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82: 10366-74.
107. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin A, Perno C. Characterization and structural analysis of HIV-1 integrase conservation. AIDS. Rev [in press].
108. Garrido C, Geretti A, de Mendoza C, Booth C, Strang A, Soriano V. Polymorphisms at the integrase gene may influence the susceptibility to integrase inhibitors in distinct HIV populations. 6th European drug resistance workshop. 26-28 March, 2008. Budapest [abstract 12].
109. Hackett J, Harris B, Holzmayer V, et al. Naturally occurring polymorphisms in HIV-1 group M, N, and O integrase: implications for integrase inhibitors. 15th CROI. February 3-6, 2008; Boston, MA [abstract 872].
110. Loizidou E, Kousiappa I, Zeinalipour-Yazdi C, et al. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Biochemistry. 2009;48:4-6.
111. Xu L, Anderson J, Ferns B, et al. Genetic diversity of integrase sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses. 2008;24:1003-7.
112. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphisms and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914-20.